Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNZ-2591 in Angelman Syndrome
NCT05011851Phase 2Completed
- Sponsor
- Neuren Pharmaceuticals Limited
- Start
- Jul 2022
- Primary completion
- May 2024
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NNZ-2591 in Angelman syndrome (AS), sponsored by Neuren Pharmaceuticals Limited. Primary endpoints: Safety and Tolerability at 13 weeks, Area Under the Curve over 24 hours at 13 weeks and 1 more. Started Jul 2022; status: completed.
02
Drugs
NNZ-2591
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NCT05011851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011851.